Haleon PLC

Haleon Plc provides personal healthcare products. The firm focus on consumer healthcare and driven by its purpose of delivering better everyday health with humanity. Its brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. The company is headquartered in Brentford, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haleon Plc engages in the provision of personal healthcare products. The firm focuses on consumer healthcare. It operates under the following geographical segments: North America, EMEA and LatAm, and Asia Pacific. The company was founded on July 18, 2022 and is headquartered in Weybridge, the United Kingdom.

Stryker

Investors with an interest in Medical - Products stocks have likely encountered both Haleon PLC Sponsored ADR (HLN) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

HLN or SYK: Which Is the Better Value Stock Right Now?

Haleon (LON: HLN) share price has moved sideways in the past few days as GlaxoSmithKline (GSK) continued selling stake in the company. The shares also reacted mildly to the latest corporate earnings, which came earlier this month.

Haleon share price has stalled: is HLN a good buy now?

Broadstone Net Lease

Bank of Nova Scotia

Chimera Investment

Canadian Imperial Bank of Commerce

Cisco Systems

Diageo

GlaxoSmithKline

Iron Mountain

Illinois Tool Works

Johnson & Johnson

Leggett & Platt

MDU Resources Group

Medical Properties Trust

NetApp

Realty Income Corp

Orion Office REIT

Paramount Global

Philip Morris

SoFi Technologies

South32 Ltd

Invesco S&P 500 High Dividend Low Volatility ETF

TotalEnergies SE

Woodside Energy Group Ltd

Investing in dividend stocks allows you to earn dividend income, the best passive income stream. Dividend Income is my primary vehicle on the road to Financial Freedom, which you can see through my Dividend Portfolio.

Dividend Income Summary: Lanny's April 2023 Summary

Haleon PLC (LSE:HLN, NYSE:HLN) has grown profits more slowly in the first quarter of 2023 amid higher costs and unhelpful currency swings. The Volatrol and Centrum manufacturer remained confident of its organic sales guidance for the full year, towards the upper end of its 4-6% range, as revenue grew 9.9% in the first three months of the year.

Haleon profits grow more slowly after mushrooming costs over past year

Pfizer

Pfizer's plan to sell its Haleon stake is not a surprise, the consumer health company's finance chief Tobias Hestler told Reuters on Wednesday.

Haleon not surprised by Pfizer stake sale plans, says CFO

Just over £700mln was added to the value of Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare company that makes Advil and Sensodyne toothpaste, following an upbeat assessment of prospects. In a trading statement, it told the market it expects organic revenue growth in 2023 to approach the high end of its projected 4%-6% range, driven by robust demand and the replenishment of respiratory health products amid a severe cold and flu season.

Haleon investors enjoy £700mln boost after trading update

As part of the launch, Excedrin is announcing the Head Care Club featuring exclusive routines from Emmy Award winning Choreographer  Derek Hough that help support everyday head health. WARREN, N.J.

Introducing Head Care from the Makers of Excedrin - a New Line of Drug-Free Dietary Supplement and Nutrient Mix Products that Address Holistic Head Health

Haleon PLC (LSE:HLN, NYSE:HLN) has "achievable" sales targets but it may struggle to meet the market's expected level of profit margins, according to Barclays. Analysts at the bank reiterated their "overweight" rating and 383p share price target.

Haleon profit margin may disappoint, says Barclays

Haleon is an underfollowed and lowly-rated market leader in the defensive consumer health sector. Recently spun out of GlaxoSmithKline, it has missed many radar screens and as a result, is hidden in plain sight.

Haleon: The Best Defense Is A Good Offense

Haleon PLC (LSE:HLN, NYSE:HLN) will find it difficult to get a significant re-rating for its shares, reckons Deutsche Bank.  Following a meeting with the FTSE 100-listed consumer healthcare group's management, analyst Tom Sykes at the bank issued a note where he said the company has "a collection of quality brands but is still levered and is still very 'new' as an entity which brings with it some risk".

Haleon: difficult for shares to get significant re-rating says analyst

Reckitt Benckiser Group PLC

City analysts were mostly in reaction mode on Thursday as the square-mile's CFA'd scribes continued to digest what has been a busy week of trading updates and results in London's mid-cap segment. Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) was tipped as a buy, at Royal Bank of Canada, so long as management execute on its plan to ‘normalise' in the coming months – that means no more write-offs and an altogether steadier few months of trading.

Reckitt Benckiser, Flutter and Haleon under Thursday's broker spotlight

Haleon PLC (LSE:HLN, NYSE:HLN) shares fell to close to a three-month low after the consumer health group posted encouraging full-year numbers but analysts said “technical factors” would lead to downgrades for the 2023 forecasts. Including a maiden dividend, Barclays said the 2022 results overall were in line with City expectations, with organic sales growth of 9% “modestly better” and profit margins “slightly worse”.

Haleon falls to near 3m low as analysts blame 'technical factors'

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. LONDON, UK / ACCESSWIRE / March 2, 2023 / Haleon plc ("Haleon") (LSE:HLN)(NYSE:HLN) today announced that its wholly-owned subsidiary GSK Consumer Healthcare Capital US LLC (the "Issuer") is exercising its option to redeem the total outstanding aggregate principal amount of its Callable Floating Rate Senior Notes due 2024 (the "Notes") on March 24, 2023 (the "Redemption Date").

Haleon PLC Announces Redemption of US$300,000,000 Outstanding Notes

Haleon PLC (LSE:HLN, NYSE:HLN) declared an inaugural dividend after its merger from GSK last year as price increases and efficiencies enabled increased profits and cash flow. The first dividend has been proposed at 2.4p per share, representing roughly 30% of adjusted earnings for the period since listing, with the board saying it intends to maintain the pay-out ratio around that level.

Haleon proposes first dividend as cash enables faster deleverage than expected

Haleon , the world's biggest standalone consumer health business with brands such as Sensodyne toothpaste and Advil painkillers, on Thursday forecast 4-6% organic revenue growth in 2023.

GSK spinoff Haleon forecasts 4-6% revenue growth in 2023

AbbVie

GE HealthCare Technologies Inc

LyondellBasell Industries

AT&T

V.F.

Verizon

There are two notable trades that are not buys this month as I decided to shuttle Haleon plc and GE HealthCare Technologies. Rarely does a spin-off these days equate to a solid real world standalone company.

Recent Stock Purchase/Sale February 2023

Haleon PLC's (LSE:HLN, NYSE:HLN) reported interest in large 'strategic scale' acquisitions, such as with Sanofi's consumer arm, have been panned by Barclays analysts as unlikely due to its need to reduce debt.  The maker of Senodybe toothpaste, Panadol pain relief and other respiratory and vitamins, minerals and supplement (VMS) brands was said by Bloomberg yesterday to be looking at transactions for the medium to long term, with Sanofi Consumer Health a potential US$30bn merger candidate.

Haleon's reported strategic M&A dismissed as 'highly unlikely' and unwanted headache

Haleon's consumer brands are strong, and its free cash flow margin is high at 16%. Net debt to EBITDA is expected to decrease to 3x in 2024.

Haleon: A Great Consumer Staples Add

Haleon, the Glaxo personal care products spin-off, is an increasingly attractive option in the over-the-counter products space, according to Credit Suisse. Results this week from J&J Consumer Health's arm are directly comparable to Haleon, adds the broker, with a 55% overlap.

Haleon looks good on J&J read across, reckons Credit Suisse

Haleon Plc is positioned as the world's largest company dedicated to the manufacture and marketing of personal care products. Haleon's power and positioning in the international market can be a bit better understood if we take into account its relationship with Pfizer and GSK plc.

Successful Data Analysis Could Be Game Changer For Haleon

Barclays has upgraded its rating on Haleon PLC (LSE:HLN, NYSE:HLN) after Zantac-related litigation in the US was dismissed, meaning it will not proceed to trial unless there is a successfully appeal. For Haleon Zantac is "substantially derisked", leaving the shares "investible again for those without the appetite for pharma litigation risk", the bank said.

Haleon upgraded by Barclays after Zantac litigation dismissed

On July 18, GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business, Haleon PLC ( HLN , Financial). By separating the slow but steady consumer health business from the higher risk-reward pharmaceutical business, the spinoff was expected to drive GSK's stock valuation multiples higher, allowing it to fund more drug development and acquisitions.

Haleon Proves Its Mettle After GSK Spinoff

Haleon plc is a new IPO that seems to have a bright future. Its conservative business model and significant moat make Haleon a long-term value play.

Haleon's Dilemma: To Wait Or Not To Wait

GSK spinoff Haleon lifts guidance as revenue rises on higher sales and volumes

Haleon PLC (LSE:HLN, NYSE:HLN) upped its outlook for organic revenue growth and profits this year as the Sensodyne and Panadol maker benefited from increasing its prices to offset cost inflation. The FTSE 100-listed consumer health group, which was spun out of GSK in the summer, said it now expects organic revenue to grow 8.0-8.5% over the full year, with adjusted operating profit margin “slightly above” last year, at actual exchange rates.

Haleon hikes organic revenue guidance after sustained price increases

News for Haleon PLC Stock (HLN)